Phenotypes associated with this allele

• Allele Symbol: Tnfrsf18^tm1Ppp
• Allele Name: targeted mutation 1, Pier Paolo Pandolfi
• Allele ID: MGI:2676557
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Tnfrsf18^tm1Ppp/Tnfrsf18^tm1Ppp	involves: 129/Sv * C57BL/6	MGI:2676558

Genotype
MGI:2676558

hm1

• Allelic Composition: Tnfrsf18^tm1Ppp/Tnfrsf18^tm1Ppp
• Genetic Background: involves: 129/Sv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:77393 )

N • homozygotes show no significant differences in the weight or cellularity of lymphoid organs, with normal T lymphocyte subpopulations detected in spleen and lymph nodes relative to wild-type mice

increased T cell apoptosis ( J:77393 )

• at 24 hrs after treatment with anti-CD3 mAb, mutant ConA-activated T lymphocytes display higher sensitivity to activation-induced apoptosis than wild-type lymphocytes both in the presence or absence of IL-2, as revealed by propidium iodide staining

abnormal T cell activation ( J:77393 )

• upon TCR/CD3-driven activation, mutant T lymphocytes exhibit increased IL-2 receptor and Fas expression and a higher IL-2 release than wild-type control T lymphocytes

increased T cell proliferation ( J:77393 )

• at 36 hrs after T lymphocyte activation with anti-CD3 mAb or anti-CD3 plus anti-CD28, mutant T lymphocytes show a significantly higher [³H]thymidine uptake relative to wild-type control cells

• addition of exogenous IL-2 slightly enhances the differences of [³H]thymidine uptake between mutant and wild-type T cells

• however, no differences in [³H]thymidine uptake are observed when mutant splenocytes or purified T cells are activated with ConA or phorbol myristate acetate plus calcium-ionophore for 36 hrs

increased interleukin-2 secretion ( J:77393 )

• upon TCR/CD3-driven activation, mutant T lymphocytes exhibit a higher IL-2 release than wild-type control T lymphocytes

hematopoietic system

increased T cell apoptosis ( J:77393 )

• at 24 hrs after treatment with anti-CD3 mAb, mutant ConA-activated T lymphocytes display higher sensitivity to activation-induced apoptosis than wild-type lymphocytes both in the presence or absence of IL-2, as revealed by propidium iodide staining

abnormal T cell activation ( J:77393 )

• upon TCR/CD3-driven activation, mutant T lymphocytes exhibit increased IL-2 receptor and Fas expression and a higher IL-2 release than wild-type control T lymphocytes

increased T cell proliferation ( J:77393 )

• at 36 hrs after T lymphocyte activation with anti-CD3 mAb or anti-CD3 plus anti-CD28, mutant T lymphocytes show a significantly higher [³H]thymidine uptake relative to wild-type control cells

• addition of exogenous IL-2 slightly enhances the differences of [³H]thymidine uptake between mutant and wild-type T cells

• however, no differences in [³H]thymidine uptake are observed when mutant splenocytes or purified T cells are activated with ConA or phorbol myristate acetate plus calcium-ionophore for 36 hrs

cellular

abnormal cell cycle ( J:77393 )

• following treatment with anti-CD3 mAb, the % of activated mutant splenocytes or purified T lymphocytes entering into the S/G2/M phases is higher than that of wild-type cells

increased T cell apoptosis ( J:77393 )

• at 24 hrs after treatment with anti-CD3 mAb, mutant ConA-activated T lymphocytes display higher sensitivity to activation-induced apoptosis than wild-type lymphocytes both in the presence or absence of IL-2, as revealed by propidium iodide staining

increased T cell proliferation ( J:77393 )

• at 36 hrs after T lymphocyte activation with anti-CD3 mAb or anti-CD3 plus anti-CD28, mutant T lymphocytes show a significantly higher [³H]thymidine uptake relative to wild-type control cells

• addition of exogenous IL-2 slightly enhances the differences of [³H]thymidine uptake between mutant and wild-type T cells

• however, no differences in [³H]thymidine uptake are observed when mutant splenocytes or purified T cells are activated with ConA or phorbol myristate acetate plus calcium-ionophore for 36 hrs